
The FDA grants accelerated approval to neladalkib for pretreated ALK-positive lung cancer, showing how next-gen kinase inhibitors tackle drug resistance
Outlook 2011
almost 16 years ago
Global Healthcare on the Ground: Global Health Progress Initiativealmost 16 years ago
Exploring Custom Synthesisalmost 16 years ago
Report from Europealmost 16 years ago
Inside ICH: ICH Meets in Japan to Finalize Key Documentsalmost 16 years ago
In the Spotlight January 2011almost 16 years ago
Outlook 2011almost 16 years ago
A Comparison of Three Extrusion Systemsalmost 16 years ago
Cost and Compliance Dominate Agenda for 2011almost 16 years ago
Improving the Quality of Product Release





